MST Access has initiated coverage of Race Oncology with a current $4.88 per share valuation. The full report can be downloaded below.
Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM). Race’s Managing Director and CEO, Mr Phil Lynch commented, “At the time we released our updated Three Pillar…
Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM. The recent identification of Bisantrene as a potent inhibitor of the Fat and obesity associated (FTO) protein, together with the…
10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…
5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…
Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will be responsible for progressing Race’s clinical development plans for Bisantrene.…
Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an inhibitor of the Fat mass and obesity-associated protein (FTO). Recent…
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology.
1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director. Effective immediately, Mr Lynch will share…
Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as regards progress in reframing the opportunity for Bisantrene in Acute…
